REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription
Starting soon · Not applicable
Conditions studied: Essential Hypertension
In brief
The REMIDEP-HTA trial is a multicenter randomized controlled study designed to evaluate whether a structured approach combining an intensive lifestyle intervention with a systematic deprescribing algorithm can achieve clinical remission of essential hypertension. \<br\>\<br\> The intervention integrates a 12-week high-intensity behavioral program focused on whole-food plant-based nutrition, progressive physical activity, sleep hygiene, and stress management, together with a hierarchical, safety-centered medication tapering protocol for antihypertensive therapy. \<br\>\<br\> The study aims to determine whether remission can be achieved through a standardized and monitored strategy that prioritizes clinical safety during medication withdrawal.
Key facts
- Study ID
- NCT07424118
- Run by
- Evelyn Vanina Re
- People needed
- 240
- Starts
- 2026-04-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-02-20
Who can join
Age: 40 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Universidad Abierta Interamericana — Buenos Aires, Buenos Aires, Argentina
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.